By testing a range of therapies in organoids grown from the patient’s own tumor sample, SEngine’s PARIS Test identified off-label therapy that proved highly successful for one ovarian cancer patient.
Read More
Precipio’s HemeScreen Cytopenia panel enabled a patient’s diagnosis without the need for a painful, invasive bone marrow biopsy.
Read More
Invivoscribe and Complete Genomics have partnered to develop and commercialize cancer biomarker tests on Complete Genomics’ NGS platforms.
Read More
The HemeScreen BCR-ABL1 Panel enabled Precipio’s clinical lab to detect a co-expression of both p190 and p210 isoforms in this patient, leading to more informed care decisions.
Read More
The expiration of the federal Public Health Emergency for COVID-19 provides new impetus for lab innovation in the post-pandemic world.
Read More